[Ophthalmologic study of patients receiving psychotropic drugs].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000009:adverse effects; D000928:Antidepressive Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy; D002386:Cataract / Q000139:chemically induced; D002561:Cerebrovascular Disorders / Q000150:complications; D002746:Chlorpromazine / Q000009:adverse effects*; D003117:Color Vision Defects / Q000139:chemically induced*; D003865:Major Depressive Disorder / Q000188:drug therapy; D005128:Eye Diseases / Q000139:chemically induced*; D005260:Female; D006423:Hemianopsia / Q000139:chemically induced*; D006801:Humans; D007908:Lens, Crystalline; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D019965:Neurocognitive Disorders / Q000188:drug therapy; D010640:Phenothiazines / Q000009:adverse effects; D010859:Pigmentation Disorders / Q000139:chemically induced; D012160:Retina; D012559:Schizophrenia / Q000188:drug therapy; D012607:Scotoma / Q000139:chemically induced*; D013881:Thioridazine / Q000009:adverse effects; D014786:Vision Disorders / Q000139:chemically induced*; D014792:Visual Acuity
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D010640:Phenothiazines; D000639:Amitriptyline; D013881:Thioridazine; D002746:Chlorpromazine
Ob oftal'mologicheskom obsledovanii bol'nykh, poluchaiushchikh psikhotropnye preparaty.